as 10-17-2025 3:56pm EST
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Founded: | 1992 | Country: | United States |
Employees: | N/A | City: | SAN DIEGO |
Market Cap: | 14.4B | IPO Year: | 1996 |
Target Price: | $164.94 | AVG Volume (30 days): | 803.5K |
Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 3.39 | EPS Growth: | 2.97 |
52 Week Low/High: | $84.23 - $154.61 | Next Earning Date: | 10-28-2025 |
Revenue: | $2,509,900,000 | Revenue Growth: | 18.42% |
Revenue Growth (this year): | 20.79% | Revenue Growth (next year): | 14.73% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
GORMAN KEVIN CHARLES | NBIX | N/A | Aug 7 '25 | Sell | $126.41 | 106,322 | $13,440,280.97 | 514,596 |
NBIX Breaking Stock News: Dive into NBIX Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
MT Newswires
8 days ago
PR Newswire
12 days ago
MT Newswires
24 days ago
PR Newswire
25 days ago
PR Newswire
a month ago
Simply Wall St.
a month ago
PR Newswire
a month ago
The information presented on this page, "NBIX Neurocrine Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.